Should I Buy Vaxart Stock in 2025? Analysis for Irish Investors

What is Vaxart?

How much is the Vaxart stock?

The price of Vaxart stock is rising this week. Currently trading at $0.4673, Vaxart has gained 3.84% over the last 24 hours and is up 2.19% for the week, with a market capitalization of $106.52 million.

As the company remains unprofitable, its P/E ratio is not applicable, and it does not pay a dividend. The stock carries a beta of 1.28, reflecting a level of volatility above the market average—important consideration for investors in Ireland seeking dynamic growth opportunities.

Our full analysis on Vaxart stock

Over the course of our most recent assessment, Vaxart’s latest financial results and the company’s share price evolution over the past three years were meticulously reviewed. Drawing on a combination of objective market data, advanced technical indicators, comparative peer analysis, and our proprietary evaluative algorithms, we observe several notable inflection points. So, why might Vaxart stock once again become a strategic entry point in the burgeoning biotech sector in 2025?

Recent Performance and Market Context

Vaxart (VXRT), currently trading at $0.4673 (as of 30 May 2025), has experienced a volatile journey over the past year—a hallmark of high-potential clinical-stage biotech stocks. While the share price remains down 42.66% year-on-year and 22.4% over six months, the past week signals a subtle yet meaningful reversal with a gain of 2.19%, accompanied by a strong intraday surge of 3.84%. The trading range for the past twelve months has stretched from a low of $0.2850 to a high of $1.0700, highlighting both the inherent risk and the scope for upside.

Importantly, recent positive developments have reshaped market sentiment:

• In May 2025, dosing commenced in the pivotal 10,000-patient Phase 2b COVID-19 clinical trial.
• The Biomedical Advanced Research and Development Authority (BARDA) granted approval to begin this trial stage, supplying government-backed endorsement and support.
• Highly promising Phase 2b data for Vaxart’s oral norovirus vaccine were published in the prestigious Science Translational Medicine.
• The completion of Phase 1 enrollment for the norovirus vaccine further advances the pipeline's diversification.

From a macro perspective, renewed attention to pandemic preparedness and the emergence of oral delivery platforms within biotechnology create a sector-wide tailwind for companies with truly innovative assets. For investors in Ireland and beyond, this context is especially favourable as governmental and institutional interest in next-generation vaccine formats continues to intensify in 2025.

Technical Analysis

Vaxart’s technical structure suggests a potential inflection point, with several indicators converging on an improved outlook:

• RSI (Relative Strength Index, 14 days): Sits at 55.83, indicating neutrality but edging towards the higher end of the range—traditionally a sign of growing buyer momentum.
• MACD: At 0.02, a neutral-to-slightly-negative signal, but one that should be watched closely for a bullish cross.
• ADX (Average Directional Index): At 20.57, points to the onset of a new trend—potentially upward as fresh catalysts unfold.

Most telling is the alignment and progression of moving averages:

• 5-day MA: $0.46 (bullish),
• 20-day MA: $0.44 (bullish),
• 50-day MA: $0.42 (bullish),
• with upside resistance at the 100-day ($0.54) and 200-day ($0.65) MAs. The proximity of support at $0.42 (coinciding with the 50-day MA) suggests this zone may serve as a springboard for renewed buying appetite.

Recent price action confined within the $0.4463–$0.4754 intraday range also underlines a period of consolidation that often precedes a breakout in biotech names—especially when paired with a clear potential newsflow pipeline.

Fundamental Analysis

Despite operational losses, Vaxart’s financial evolution is compelling when reframed through a growth lens:

• Revenue Growth: 2024 revenues soared to $28.7M—a staggering 289% increase over 2023—thanks to BARDA funding and pipeline milestone revenues. Trailing twelve-month (TTM) revenues now stand at $47.4M.
• Profitability: Although the company remains loss-making (TTM net loss: –$58.1M), the loss has narrowed (–18.8% year-on-year), reflecting prudent cost discipline amid scaling operations.
• Valuation: While the absence of a positive P/E ratio is typical for clinical-stage biotech firms, the current $106.5M market capitalisation and low price/sales (P/S) multiples relative to sector peers signal attractive entry criteria for risk-tolerant investors.
• Structural Strengths: Vaxart’s IP-protected, proprietary oral vaccine platform enables room-temperature stable vaccine delivery—an immense logistical and cost advantage over injectable competitors. The broad and growing pipeline (COVID-19, norovirus, flu, HPV therapeutic) creates multiple shots on goal, mitigating single-asset risk.

Innovation, a diversified portfolio, and a credible business model all reinforce Vaxart’s emerging leadership within next-generation immunisation.

Volume and Liquidity

Vaxart’s robust average daily volume—nearly 985,000 shares—indicates heightened investor interest and ensures excellent tradability for both Irish and global investors. With over 222 million shares in the float, the stock remains highly liquid for a small-market-cap biotech, which can be pivotal in facilitating swift price adjustments in response to positive newsflow.

Sustained activity at current levels signals confidence, helping to support valuation and underpinning the case for dynamic price discovery should upcoming catalysts materialise positively.

Catalysts and Positive Outlook

Looking ahead, several clear catalysts have the potential to meaningfully revalue the stock:

• COVID-19 Phase 2b Results: The recently launched 10,000-patient trial, supported by BARDA, has the capacity to propel valuation dramatically if efficacy data mirror earlier stages.
• Norovirus Data: Topline Phase 1 results for the norovirus tablet vaccine are due mid-2025; positive outcomes could accelerate commercialisation and perhaps partnership activity.
• Oral Vaccine Platform: The company’s proprietary, non-injectable vaccine delivery offers unique advantages in manufacturability, storage, and global distribution, aligning well with increasing logistical challenges faced by governments and NGOs.
• ESG/Global Health Impact: As global health authorities demand scalable, accessible vaccination solutions, Vaxart’s approach aligns with key ESG and sustainability metrics, enhancing its long-term appeal to institutional investors.

Consensus analyst targets are strikingly bullish: Two covering analysts issue a “Strong Buy” recommendation with a $3.00 price objective, implying a potential upside exceeding 540% from current levels.

Investment Strategies

Given Vaxart’s positioning, the following arguments characterise its potential across investment time horizons:

• Short-Term (Swing Trading & Newsflow):
• Strong technical support at $0.42 may serve as an attractive accumulation point for traders seeking a rebound, backed by imminent news catalysts.
• High volatility presents tactical trading opportunities around ongoing trial announcements and regulatory updates.
• Medium-Term (2025 Catalysts):
• The timeline of key data readouts (COVID-19, norovirus) and strategic developments should maintain a steady flow of substantive news through H2 2025.
• The current price zone, combined with consolidation patterns, seemingly represents an ideal pre-catalyst entry.
• Long-Term (Structural Upside):
• For investors seeking transformative plays in biotechnology, Vaxart’s patented oral vaccine technology and expanding pipeline underpin significant re-rating potential if clinical milestones are met.
• Unique competitive positioning, strong IP, and the trend toward non-injectable immunisation suggest potential for sustained, outsized returns in the event of success.

Is it the Right Time to Buy Vaxart?

In summary, Vaxart combines rare attributes—rapid revenue expansion, technology with scale-up potential, and an imminent catalyst pipeline—underpinned by robust trading interest and credible institutional backing. Technical and fundamental indicators appear to align for a new bullish phase, especially with support for the current price structure and an encouraging backdrop from both macro (sector-wide vaccine innovation) and micro (company-specific advances) vantage points.

With momentum building from both a technical and news pipeline perspective, and the company’s differentiated oral vaccine approach answering a clear unmet need, Vaxart stock seems to represent an excellent opportunity within the growth biotech landscape at this juncture. The fundamentals justify renewed investor interest, and consensus targets reflect conviction in the upside potential. As the next series of clinical milestones approach, Vaxart may be entering a new phase of market recognition and value creation—making this a moment that investors should consider seriously as a strategic entry point into breakthrough biotechnology for 2025 and beyond.

In a market increasingly driven by innovation and scalability, Vaxart stands at the confluence of momentum and creative disruption—a combination that often heralds outsized rewards for bold, disciplined investors.

How to buy Vaxart stock in Ireland?

Buying Vaxart shares online is both straightforward and secure for investors in Ireland, thanks to access to regulated brokers that operate under EU and MiFID II rules. You can choose between two main approaches: spot buying, where you own the shares outright, or CFD trading, which lets you speculate on price movements without owning the underlying asset. Both methods can be initiated fully online, with instant order execution and strong client protections. Selecting the best broker for your needs is essential—see our comparison of leading platforms and fee structures further down this page.

Spot Buying

A cash (spot) purchase means you buy Vaxart shares directly on the NASDAQ, becoming the legal owner. Most Irish brokers charge a fixed commission for this service, typically between €5–€10 per trade, often shown in euro but may be billed in USD for US stocks.

Example

Suppose Vaxart is trading at $0.47 per share. With a $1,000 investment, you could buy about 2,120 shares (allowing for a brokerage fee of approximately $5).

Gain scenario

If the share price increases by 10%, your holdings would be valued at $1,100. This equates to a gross gain of $100, or +10% return on your initial investment (before possible currency conversion or taxes).

Trading via CFD

CFD (Contract for Difference) trading lets you speculate on Vaxart’s price movement without owning the underlying shares. With CFDs, you can trade long (buy) or short (sell), and benefit from leverage—amplifying both potential gains and losses. Fees include the bid-ask spread and overnight funding if you hold your position beyond the trading day.

Example

You open a CFD on Vaxart shares with a $1,000 margin and 5x leverage. This gives you effective market exposure of $5,000.

Gain scenario

Should the price rise by 8%, your CFD position would return 8% × 5 = 40%, for a profit of $400 on your $1,000 stake (excluding fees and charges).

Final Advice

Before investing, it’s crucial to compare brokers on their fee schedules, minimum trade sizes, and overall conditions—costs can make a significant difference to your returns, especially on lower-priced shares like Vaxart. Whether you prefer owning the stock directly or trading short-term via CFDs depends on your risk profile, investment horizon, and objectives. There’s no universal best approach—feel free to consult the comparator lower on this page to find the platform that suits your needs.

Our 7 tips for buying Vaxart stock

The latest news about Vaxart

Vaxart’s oral COVID-19 vaccine enters large-scale Phase 2b trial dosing in May 2025. This month, Vaxart began dosing for the 10,000-participant cohort of its pivotal Phase 2b trial for the oral COVID-19 vaccine candidate, following formal approval by the US government agency BARDA. This milestone is significant as it marks the transition to a late-stage study supported by government funding, enhancing the visibility and credibility of Vaxart’s program globally. For Ireland, where oral vaccine delivery could support higher public compliance and cold-chain logistics are challenging in some settings, the underlying technology of Vaxart has potential long-term benefits. Additionally, positive regulatory signals in the US often facilitate smoother pathways for future European authorisations and potential partnerships.

Vaxart reports strong Q1 2025 financials, beating EPS expectations and showing revenue acceleration. For the quarter ended March 2025, Vaxart posted a better-than-expected loss per share of -$0.04, outperforming consensus by over 63%. The company’s trailing twelve-month revenue soared to $47.4M, reflecting sustained demand and successful R&D financing rounds. Irish institutional and retail investors gain confidence from such outperformance, particularly as biotech indexes are highly sensitive to positive earnings surprises. The company’s progress on its oral vaccine portfolio positions it competitively for potential commercial entry into EU markets, including Ireland, subject to future regulatory clearance.

Positive Phase 2b norovirus vaccine data published in a top scientific journal in May 2025. Vaxart recently released new peer-reviewed clinical data for its norovirus vaccine candidate in Science Translational Medicine. The favorable results reinforce the competitive advantage of the company’s oral vaccine platform, which could significantly impact disease prevention strategies in regions like Ireland, where norovirus outbreaks are a recurring public health issue. This publication increases the company’s scientific profile within the global healthcare community, potentially accelerating future trials and eventual product rollout across the European landscape.

Technical indicators turn bullish short-term, with key moving averages now signaling a buy. Over the past week, Vaxart’s share price rose 2.19% to $0.4673, outperforming peers and with a 5-, 20-, and 50-day moving average all trending upward. Though the stock remains below its 100- and 200-day averages, these short-term technical signals suggest growing momentum. For Irish analysts monitoring US-listed biotech exposure, such signals are important, as they reflect renewed investor confidence following clinical and financial catalysts, and can inform tactical decisions about portfolio allocation or hedging.

Consensus analyst outlook remains “Strong Buy” with a $3.00 price target, driven by pipeline momentum and government support. Current analyst consensus has maintained a strong buy rating, with a $3.00 price target implying substantial upside from current levels, following the key milestones achieved this month. The recent addition of CFO Jeroen Grasman and recognized government partnerships with BARDA further strengthen Vaxart’s financial governance and funding credibility—both important for Irish professional investors seeking exposure to innovative, yet de-risked, US biotech entities. As the clinical pipeline advances and strategic collaborations mature, Vaxart’s platform is increasingly relevant to international health strategies, including those targeting the Irish market.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.